The 20-foot wide mansion was built in 1869 along with three others on East 74th Street, and was significantly redesigned in 1919 by architect George Blum, who added its historically significant limestone facade, French windows and a green-tiled roof.

This month, Flagstar offloaded $142 million of that portfolio, finding a buyer in Howard Lutnick’s Cantor Fitzgerald, PincusCo reported. A spokesperson for Cantor Fitzgerald did not return a ...

Cantor Fitzgerald maintained an Underweight rating on Airbnb Inc . (NASDAQ:ABNB) with a price target of $117.00. The firm's analyst, Deepak Mathivanan, highlighted Airbnb's significant investments in new market expansion,

Cantor Fitzgerald upgraded Lam Research (LRCX) to Overweight from Neutral with a price target of $100, up from $95. The firm had suggested

Donald Trump's commerce secretary nominee told his US Senate confirmation hearing Wednesday he favors "across-the-board" tariffs targeting countries rather than products, while signaling a hawkish China stance.

Cantor Fitzgerald assumed coverage of Cidara Therapeutics (CDTX) with an Overweight rating. Cidara’s lead asset CD388, an anti-viral that targets neuraminidase, an essential surface receptor ...

In preparation for the launch, Cantor Fitzgerald hosted a discussion with a Senior Director of Product Development at UnitedHealth (NYSE:UNH). The conversation provided insights into the coverage ...

In a recent industry report focused on Biotechnology stocks, particularly those innovating in neurology and psychiatry, Cantor Fitzgerald highlighted a positive outlook despite broader market uncertainties.

Fintel reports that on January 29, 2025, Cantor Fitzgerald upgraded their outlook for Beam Therapeutics (NasdaqGS:BEAM) from Neutral to Overweight. Analyst Price Forecast Suggests 87.91% Upside As of January 29,

Investment analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for Datadog in a research report issued to clients and investors on Tuesday, January 21st. Cantor Fitzgerald analyst T.

Cantor Fitzgerald currently has a “Overweight” rating and a $6.00 price target on the stock. The consensus estimate for VinFast Auto’s current full-year earnings is ($1.03) per share. Get ...

Cantor Fitzgerald initiated coverage on shares of Cidara Therapeutics (NASDAQ:CDTX), assigning an Overweight rating to the biotechnology firm. The coverage, led by analyst Eric Schmidt, highlighted the potential of CDTX's leading drug candidate,